Affymax Competitors

Affymax (OTCMKTS:AFFY) and Amgen (NASDAQ:AMGN) are both medical companies, but which is the better business? We will contrast the two businesses based on the strength of their institutional ownership, profitability, earnings, analyst recommendations, valuation, risk and dividends.

Profitability

This table compares Affymax and Amgen's net margins, return on equity and return on assets.

Analyst Recommendations

This is a breakdown of recent ratings and target prices for Affymax and Amgen, as provided by MarketBeat.com.

Amgen has a consensus price target of $255.6190, suggesting a potential upside of 1.91%. Given Amgen's higher probable upside, analysts clearly believe Amgen is more favorable than Affymax.

Insider and Institutional Ownership

75.2% of Amgen shares are held by institutional investors. 1.6% of Affymax shares are held by insiders. Comparatively, 0.4% of Amgen shares are held by insiders. Strong institutional ownership is an indication that endowments, large money managers and hedge funds believe a stock is poised for long-term growth.

Risk and Volatility

Affymax has a beta of 2.77, indicating that its share price is 177% more volatile than the S&P 500. Comparatively, Amgen has a beta of 0.76, indicating that its share price is 24% less volatile than the S&P 500.

Valuation & Earnings

This table compares Affymax and Amgen's top-line revenue, earnings per share (EPS) and valuation.

Amgen has higher revenue and earnings than Affymax.

Summary

Amgen beats Affymax on 7 of the 9 factors compared between the two stocks.

Gilead Sciences (NASDAQ:GILD) and Affymax (OTCMKTS:AFFY) are both medical companies, but which is the better investment? We will contrast the two companies based on the strength of their valuation, analyst recommendations, dividends, risk, profitability, institutional ownership and earnings.

Insider and Institutional Ownership

76.4% of Gilead Sciences shares are held by institutional investors. 0.1% of Gilead Sciences shares are held by company insiders. Comparatively, 1.6% of Affymax shares are held by company insiders. Strong institutional ownership is an indication that large money managers, endowments and hedge funds believe a company will outperform the market over the long term.

Analyst Recommendations

This is a summary of current ratings and recommmendations for Gilead Sciences and Affymax, as reported by MarketBeat.

Gilead Sciences currently has a consensus price target of $99.7391, suggesting a potential upside of 47.87%. Given Gilead Sciences' higher possible upside, equities analysts plainly believe Gilead Sciences is more favorable than Affymax.

Volatility & Risk

Gilead Sciences has a beta of 0.51, suggesting that its share price is 49% less volatile than the S&P 500. Comparatively, Affymax has a beta of 2.77, suggesting that its share price is 177% more volatile than the S&P 500.

Profitability

This table compares Gilead Sciences and Affymax's net margins, return on equity and return on assets.

Earnings & Valuation

This table compares Gilead Sciences and Affymax's gross revenue, earnings per share and valuation.

Gilead Sciences has higher revenue and earnings than Affymax.

Summary

Gilead Sciences beats Affymax on 7 of the 9 factors compared between the two stocks.

Affymax (OTCMKTS:AFFY) and Vertex Pharmaceuticals (NASDAQ:VRTX) are both medical companies, but which is the better stock? We will contrast the two businesses based on the strength of their profitability, valuation, earnings, dividends, risk, analyst recommendations and institutional ownership.

Profitability

This table compares Affymax and Vertex Pharmaceuticals' net margins, return on equity and return on assets.

Earnings & Valuation

This table compares Affymax and Vertex Pharmaceuticals' revenue, earnings per share (EPS) and valuation.

Vertex Pharmaceuticals has higher revenue and earnings than Affymax.

Risk & Volatility

Affymax has a beta of 2.77, meaning that its stock price is 177% more volatile than the S&P 500. Comparatively, Vertex Pharmaceuticals has a beta of 0.79, meaning that its stock price is 21% less volatile than the S&P 500.

Institutional & Insider Ownership

92.2% of Vertex Pharmaceuticals shares are held by institutional investors. 1.6% of Affymax shares are held by insiders. Comparatively, 0.7% of Vertex Pharmaceuticals shares are held by insiders. Strong institutional ownership is an indication that hedge funds, endowments and large money managers believe a company will outperform the market over the long term.

Analyst Recommendations

This is a breakdown of recent recommendations and price targets for Affymax and Vertex Pharmaceuticals, as provided by MarketBeat.

Vertex Pharmaceuticals has a consensus target price of $293.4737, suggesting a potential upside of 37.99%. Given Vertex Pharmaceuticals' higher possible upside, analysts clearly believe Vertex Pharmaceuticals is more favorable than Affymax.

Summary

Vertex Pharmaceuticals beats Affymax on 8 of the 10 factors compared between the two stocks.

Regeneron Pharmaceuticals (NASDAQ:REGN) and Affymax (OTCMKTS:AFFY) are both medical companies, but which is the superior stock? We will compare the two companies based on the strength of their profitability, risk, valuation, earnings, institutional ownership, analyst recommendations and dividends.

Institutional & Insider Ownership

85.0% of Regeneron Pharmaceuticals shares are owned by institutional investors. 11.8% of Regeneron Pharmaceuticals shares are owned by insiders. Comparatively, 1.6% of Affymax shares are owned by insiders. Strong institutional ownership is an indication that large money managers, hedge funds and endowments believe a company will outperform the market over the long term.

Analyst Recommendations

This is a breakdown of recent ratings and price targets for Regeneron Pharmaceuticals and Affymax, as provided by MarketBeat.com.

Regeneron Pharmaceuticals presently has a consensus price target of $656.3810, indicating a potential upside of 29.43%. Given Regeneron Pharmaceuticals' higher possible upside, analysts clearly believe Regeneron Pharmaceuticals is more favorable than Affymax.

Valuation and Earnings

This table compares Regeneron Pharmaceuticals and Affymax's revenue, earnings per share and valuation.

Regeneron Pharmaceuticals has higher revenue and earnings than Affymax.

Profitability

This table compares Regeneron Pharmaceuticals and Affymax's net margins, return on equity and return on assets.

Risk and Volatility

Regeneron Pharmaceuticals has a beta of 0.3, meaning that its stock price is 70% less volatile than the S&P 500. Comparatively, Affymax has a beta of 2.77, meaning that its stock price is 177% more volatile than the S&P 500.

Summary

Regeneron Pharmaceuticals beats Affymax on 8 of the 9 factors compared between the two stocks.

Biogen (NASDAQ:BIIB) and Affymax (OTCMKTS:AFFY) are both medical companies, but which is the superior stock? We will compare the two companies based on the strength of their profitability, risk, valuation, earnings, institutional ownership, analyst recommendations and dividends.

Institutional & Insider Ownership

83.5% of Biogen shares are owned by institutional investors. 0.5% of Biogen shares are owned by insiders. Comparatively, 1.6% of Affymax shares are owned by insiders. Strong institutional ownership is an indication that large money managers, hedge funds and endowments believe a company will outperform the market over the long term.

Analyst Recommendations

This is a breakdown of recent ratings and price targets for Biogen and Affymax, as provided by MarketBeat.com.

Biogen presently has a consensus price target of $305.5714, indicating a potential upside of 11.51%. Given Biogen's higher possible upside, analysts clearly believe Biogen is more favorable than Affymax.

Valuation and Earnings

This table compares Biogen and Affymax's revenue, earnings per share and valuation.

Biogen has higher revenue and earnings than Affymax.

Profitability

This table compares Biogen and Affymax's net margins, return on equity and return on assets.

Risk and Volatility

Biogen has a beta of 0.53, meaning that its stock price is 47% less volatile than the S&P 500. Comparatively, Affymax has a beta of 2.77, meaning that its stock price is 177% more volatile than the S&P 500.

Summary

Biogen beats Affymax on 7 of the 9 factors compared between the two stocks.

Affymax (OTCMKTS:AFFY) and Alexion Pharmaceuticals (NASDAQ:ALXN) are both medical companies, but which is the better business? We will compare the two companies based on the strength of their earnings, valuation, risk, institutional ownership, dividends, profitability and analyst recommendations.

Analyst Ratings

This is a summary of recent ratings and recommmendations for Affymax and Alexion Pharmaceuticals, as reported by MarketBeat.com.

Alexion Pharmaceuticals has a consensus target price of $159.3158, indicating a potential downside of 7.37%. Given Alexion Pharmaceuticals' higher probable upside, analysts clearly believe Alexion Pharmaceuticals is more favorable than Affymax.

Profitability

This table compares Affymax and Alexion Pharmaceuticals' net margins, return on equity and return on assets.

Institutional & Insider Ownership

87.3% of Alexion Pharmaceuticals shares are owned by institutional investors. 1.6% of Affymax shares are owned by company insiders. Comparatively, 4.0% of Alexion Pharmaceuticals shares are owned by company insiders. Strong institutional ownership is an indication that hedge funds, large money managers and endowments believe a stock will outperform the market over the long term.

Risk & Volatility

Affymax has a beta of 2.77, indicating that its share price is 177% more volatile than the S&P 500. Comparatively, Alexion Pharmaceuticals has a beta of 1.33, indicating that its share price is 33% more volatile than the S&P 500.

Valuation & Earnings

This table compares Affymax and Alexion Pharmaceuticals' top-line revenue, earnings per share (EPS) and valuation.

Alexion Pharmaceuticals has higher revenue and earnings than Affymax.

Summary

Alexion Pharmaceuticals beats Affymax on 8 of the 9 factors compared between the two stocks.